A Bone Resorption Markers test is a specialized diagnostic blood or urine assay used to measure the rate at which bone tissue is broken down by osteoclasts.
Key markers typically evaluated include:
* C-Telopeptide (CTX): A primary fragment released into the bloodstream during the breakdown of type I collagen in bones.
* N-Telopeptide (NTX): Another collagen breakdown byproduct frequently measured in urine samples to track degradation speed.
Physicians utilize this test to assess active bone loss, diagnose metabolic bone disorders, and monitor the effectiveness of anti-resorptive medications like bisphosphonates in patients undergoing osteoporosis treatment.

A Both FT-Medium Biopsy 1-3cm test involves the targeted extraction and pathological examination of tissue lesions measuring between one and three centimeters.
This diagnostic procedure is utilized when imaging or clinical evaluations detect tissue abnormalities requiring definitive cellular analysis.
Key aspects of the procedure include:
* Target Size: Focuses on lesions ranging from 1 to 3 centimeters in dimension.
* Tissue Sampling: Secures representative cellular specimens for microscopic evaluation.
* Pathology Assessment: Identifies malignancy, inflammation, or abnormal tissue growth.
Clinicians rely on this test to confirm diagnoses, stage diseases, and guide personalized treatment plans.

The BRAF V600 Mutation Detection FFPE Tissue test is a specialized molecular diagnostic assay designed to identify specific genetic mutations within the BRAF gene using formalin-fixed, paraffin-embedded tissue samples.
This test primarily targets the V600E and V600K amino acid substitutions, which result in constitutive activation of the MAPK/ERK signaling pathway and drive cellular proliferation in various cancers.
Oncologists utilize this diagnostic tool to evaluate patients with melanoma, colorectal cancer, and non-small cell lung cancer. Identifying a BRAF V600 mutation is critical for determining eligibility for targeted therapies, including specific BRAF and MEK inhibitors.

A brain tumor test encompasses diagnostic evaluations used to detect, locate, and characterize abnormal growths within the central nervous system.
Key diagnostic modalities typically involve:
* Magnetic Resonance Imaging (MRI): The gold-standard imaging technique providing high-resolution anatomical views of brain tissue.
* CT Scans: Utilized for rapid initial imaging to identify structural changes, bleeding, or calcifications.
* Biopsy: The definitive surgical or stereotactic extraction of tissue samples for microscopic and molecular pathology.
Clinicians rely on these procedures to determine tumor grading, differentiate between benign and malignant lesions, and formulate individualized neuro-oncology treatment plans.

The BRCA deletion/duplication analysis test is a comprehensive molecular assay used to identify large genomic rearrangements—such as deletions or duplications of one or more exons—within the BRCA1 and BRCA2 genes.
Standard sequencing panels primarily detect point mutations and small insertions or deletions, which can miss larger structural alterations. This specialized test detects these missing segments using advanced methodologies like multiplex ligation-dependent probe amplification (MLPA).
Clinicians utilize this diagnostic tool alongside standard mutation screening for patients with a strong personal or family history of breast and ovarian cancer, ensuring a complete genetic evaluation for risk assessment.

The BRCA 1/2 Germline Test is a specialized hereditary genetic assay designed to detect inherited mutations within the BRCA1 and BRCA2 genes.
Key aspects of this molecular test include:
* Sample Collection: Typically performed using a simple blood or saliva sample to extract constitutional DNA.
* Inherited Mutations: Identifies germline variants passed down from parents that significantly elevate lifetime risks for developing hereditary breast, ovarian, and related cancers.
* Clinical Utility: Empowers individuals and healthcare providers to implement proactive surveillance, preventive risk-reducing strategies, and targeted therapeutic options such as PARP inhibitors.